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Abstract: The first step in vision is the absorption of photons by the photopigments in cone and
rod photoreceptors. After initial amplification within the phototransduction cascade the signal
is translated into an electrical signal by the action of cyclic nucleotide-gated (CNG) channels.
CNG channels are ligand-gated ion channels that are activated by the binding of cyclic guanosine
monophosphate (cGMP) or cyclic adenosine monophosphate (cAMP). Retinal CNG channels
transduce changes in intracellular concentrations of cGMP into changes of the membrane potential
and the Ca2+ concentration. Structurally, the CNG channels belong to the superfamily of pore-loop
cation channels and share a common gross structure with hyperpolarization-activated cyclic
nucleotide-gated (HCN) channels and voltage-gated potassium channels (KCN). In this review,
we provide an overview on the molecular properties of CNG channels and describe their physiological
role in the phototransduction pathways. We also discuss insights into the pathophysiological role of
CNG channel proteins that have emerged from the analysis of CNG channel-deficient animal models
and human CNG channelopathies. Finally, we summarize recent gene therapy activities and provide
an outlook for future clinical application.
Keywords: CNG; cyclic nucleotide-gated channel; vision; channelopathies; Ca2+; knockout;
photoreceptor; cGMP; gene therapy
1. Introduction
Cyclic nucleotides, such as cAMP and cGMP, regulate the activity of several classes of proteins
including cyclic nucleotide-binding domain (CNBD)-containing cation channels. Structurally, cyclic
nucleotide-regulated channels belong to the superfamily of pore-loop cation channels [1]. In vertebrates,
three subfamilies of CNBD-containing ion channels exist: the CNG, the HCN and the KCN channels [2,3].
These channels share a similar principal architecture but differ from each other in terms of their
activation mode and ion selectivity. Cyclic nucleotide-gated (CNG) channels are strictly ligand-gated
because their opening requires the binding of cGMP or cAMP. CNG channels have been also found in
several non-vertebrate species including insect species and C. elegans. In mammals, the CNG channel
family comprises six homologous members (CNGA1-4, CNGB1 and CNGB3) encoding for structurally
similar A and B subunits that assemble in distinct combinations into cell type-specific heterotetrameric
complexes [4] (Figure 1). The A subunits confer the principal channel properties, whereas the B subunits
are essential for proper outer segment localization and contribute specific biophysical properties (e.g.,
fast gating kinetics) to the native channel complex [2].
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Figure 1. (A) Membrane topology of CNG channel subunits. 1–6, transmembrane segment 1–6; C, 
carboxy-terminus; CNBD, cyclic nucleotide binding domain; N, amino-terminus. (B) Model of the 
CNG channel complex embedded in the plasma membrane based on the TAX-4 structure. (C) Top 
and bottom views of the tetrameric TAX-4 C. elegans CNG channel complex. (D) Subunit composition 
of the CNG channels from rods and cones. A1, CNGA1; A3, CNGA3; B1, CNGB1; B3, CNGB3. 
Structures in this figure were generated with the RSCB PDB 3D View tool (www.rcsb.org/3d-view/) 
based on PDB 5H3O. 
2. Structure, Basic Properties and Activation of CNG Channels 
CNG channels form a distinct branch within the superfamily of voltage-gated-like (VGL) 
channels [1,5]. In mammals, the CNG channel family comprises six homologous members, which are 
classified as A subunits (CNGA1-4) and B subunits (CNGB1 and CNGB3). A subunits and B subunits 
share the same principal membrane topology. Each of these subunits possesses a transmembrane 
channel core consisting of six α-helical segments (S1–S6), a reentrant pore (P) loop between S5 and 
S6, and cytosolic N- and C-termini. The CNBD is located in the C-terminus and is connected to the 
S6 by the C-linker. Native CNG channels in photoreceptor outer segments are heterotetramers 
assembled by three A subunits (CNGA1 in rods and CNGA3 in cones) and one B subunit (CNGB1 in 
rods and CNGB3 in cones) [6–9]. So far, no structure of mammalian CNG channels is available. 
However, a structure of the CNG channel from C. elegans TAX-4 has been recently determined by 
single-particle electron cryo-microscopy [10]. Like other CNBD-containing channels [3], CNG 
channels are tetramers with the four subunits arranged around the centrally located pore [10]. The 
ion conducting pore is lined by the P-loops and the S6 segments of the four subunits. The TAX-4 
voltage-sensor-like (VSL) domain is unique among known VSL structures as it appears segmented. 
This segmentation might preclude voltage-dependent movements within the membrane and thus 
help explain the lack of voltage-dependent gating of CNG channels [10]. However, the TAX-4 
structure only reflects the cGMP-bound open state and a closed state structure is missing. Based on 
comparisons of available open and closed state structures from related channels and previous 
mutagenesis studies, activation of CNG channels is thought to involve coordinated movements of at 
least three basic elements, the CNBD, the C-linker and the channel gate [10–15]. Binding of cyclic 
nucleotides to the CNBD leads to a rotational change of the entire C-terminus relative to the pore. 
The C-linker, a domain that allosterically couples cyclic nucleotide-binding to the channel gate also 
follows this rotation and partially moves upwards. The channel gate located in the intracellular 
portion of the S6 segment is constricted and maintained in the closed state presumably by steady 
forces from the C-linker [16,17]. Upon binding of the ligand, the movements described above relieve 
Figure 1. (A) Membrane topology of CNG channel subunits. 1–6, transmembrane segment 1–6;
C, carboxy-terminus; CNBD, cyclic nucleotide binding domain; N, amino-terminus. (B) Model of the
CNG channel complex embedded in the plasma membrane based on the TAX-4 structure. (C) Top and
bottom views of the tetrameric TAX-4 C. elegans CNG channel complex. (D) Subunit composition of
the CNG channels from rods and cones. A1, CNGA1; A3, CNGA3; B1, CNGB1; B3, CNGB3. Structures
in this figure were generated with the RSCB PDB 3D View tool (www.rcsb.org/3d-view/) based on
PDB 5H3O.
2. Structure, Basic Properties and Activation of CNG Channels
CNG channels for a distinct branch within the superfamily of voltag -gated-like (VGL)
channels [1,5]. In mammals, the CNG channel family comprises six homologous members, which are
cla sifi d as A subunits (CNGA1-4) and B subunits (CNGB1 and CNGB3). A ubuni s and B subunits
share the sam principal membrane topology. Each of thes subunits possesses a transmembrane
channel core consisting of six α-helical segments (S1–S6), a reentrant pore (P) loop between S5 and S6,
and cytosolic N- and C-termini. The CNBD is located in the C-terminus and is connected to the S6 by
the C-linker. Native CNG channels in photoreceptor outer segments are heterotetramers assembled
by three A subunits (CNGA1 in rods and CNGA3 in cones) and one B subunit (CNGB1 in rods and
CNGB3 in cones) [6–9]. So far, no structure of mammalian CNG channels is available. However,
a structure of the CNG channel from C. elegans TAX-4 has been recently determined by single-particle
electron cryo-microscopy [10]. Like other CNBD-containing channels [3], CNG channels are tetramers
with the four subunits arranged around the centrally located pore [10]. The ion conducting pore
is lined by the P-loops and the S6 segments of the four subunits. The TAX-4 voltage-sensor-like
(VSL) domain is unique among known VSL structures as it appears segmented. This segmentation
might preclude voltage-dependent movements within the membrane and thus help explain the lack
of voltage-dependent gating of CNG channels [10]. However, the TAX-4 structure only reflects the
cGMP-bound open state and a closed state structure is missing. Based on comparisons of available
open and closed stat structures from related channels and previous mutagenesis stu ies, activation
of CNG channels is thought to involve c ordin ted mov ments of at least three basic elements,
the CNBD, the C-linker and the channel gate [10–15]. Binding of cycl c nucleotides to the CNBD
leads to a rotati nal ch ge of the entire C-terminus relative to the pore. The C-linker, a domain
that allosterically couples cyclic nucleoti e-binding to the channel gate also follows this rotation and
partially moves upwards. The channel gate located in the intracellular portion of the S6 segment is
constricted and maintained in the closed state presumably by steady forces from the C-linker [16,17].
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Upon binding of the ligand, the movements described above relieve the inhibitory forces of the C-linker
and the channel pore becomes delated, thereby allowing for ion permeation.
While all six mammalian CNG channel subunits share significant sequence homology, only CNGA1,
CNGA2 and CNGA3 can form functional homotetrameric channels in heterologous expression systems.
The remaining subunits (CNGA4, CNGB1 and CNGB3) do not assemble to functional homotetramers.
However, when present in heterotetrameric CNG channel complexes, they confer key functional
properties specific for native CNG channels (e.g., single channel flickering, altered affinity for cyclic
nucleotides, distinct permeation properties, regulation by Ca2+) (for detailed review see [2,18]).
CNG channels are non-selective for several monovalent or divalent cations, such as Na+ and
K+, Ca2+ and Mg2+. However, Ca2+ and Mg2+ can also act as a voltage-dependent blocker of
monovalent cation permeability [19,20]. Another characteristic feature of CNG channels is the lack
of desensitization or inactivation upon exposure to cyclic nucleotides. In addition, CNG channels
show Ca2+-dependent feedback inhibition, which is thought to be calmodulin (CaM)-mediated [21,22].
In rods, Ca2+-inhibition is conferred by binding of CaM to an IQ-type binding site located at the
N-terminus of the CNGB1 subunit [23,24]. In cone photoreceptors this inhibitory effect is more
pronounced and most likely mediated by another Ca2+-binding protein termed CNG-modulin [25].
3. Signal Transduction in Photoreceptors
Rod and cone photoreceptors possess similar, but distinct phototransduction pathways which
fulfill the required initial processing of visual stimuli at different ambient light conditions (Figure 2).
Rods mediate vision at dim light levels, whereas vision at higher light levels (e.g., daylight) is provided
by cones with minor contribution from rods. The cone visual system also enables color vision
as it can discriminate between wavelengths by comparing inputs from two (in most vertebrates)
or three (in humans and some non-human primates) types of cones equipped with different cone
opsin variants (short-, medium- and long-wave sensitive) with distinct spectral sensitivities [26,27].
In both rods and cones, signal transduction follows the same principle and is facilitated by enzymes
controlling the levels of the second messenger cGMP. cGMP in turn controls the activation of the CNG
channel present in the plasma membrane of the photoreceptor outer segment (Figure 1). In the dark,
constant activity of transmembrane guanylyl cyclases [28,29] results in high levels of cGMP, which
maintains the CNG channel in an opened conformation. As mentioned in the previous section, CNG
channels carry a steady non-inactivating Na+ and Ca2+ current (“dark current”) which depolarizes
the photoreceptor promoting glutamate release at the photoreceptor synaptic terminal. Following
light stimulation photopigments (opsins) initiate a G protein (transducin) mediated signaling cascade
leading to activation of a cGMP phosphodiesterase (PDE6). PDE6 hydrolyses cGMP and thereby leads
to closure of the CNG channel. Consequently, the photoreceptor hyperpolarizes and the synaptic
glutamate release decreases. CNG channels provide the only source for Ca2+ influx into rod and
cone outer segments [2,30,31]. Ca2+ entry is balanced by Ca2+ extrusion through the activity of
a Na+/Ca2+-K+ exchanger [31–35]. Thus, light stimulation of photoreceptors results in a decrease of
the intracellular Ca2+ concentration because it shuts down Ca2+ entry via the CNG channels while
the Na+/Ca2+-K+ exchanger continues to clear Ca2+ from the cytosol. The reduced Ca2+ level upon
light absorption contributes to the recovery from light response by several mechanisms including
phosphorylation of visual pigments and PDE6, as well as restoration of cGMP levels by guanylyl
cyclase activating proteins (GCAPs; [36])-mediated activation of the guanylyl cyclase.
Photoresponses measured from isolated rods and cones differ in sensitivity and kinetics [2,37].
Rod and cone CNG channels share the same principle functional properties and differ only in some
specific features. Notable examples are the higher Ca2+-permeability of the cone CNG channel and the
stronger Ca2+-dependent inhibition of the ligand-sensitivity in the rod CNG channel [2,38]. However,
these differences cannot explain the differences in rod and cone photoresponses, which most likely
result from multiple distinct signaling cascade molecules and distinct morphological characteristics
(e.g., outer segment compartmentalization).
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Figure 2. (A,B) Phototransduction in mouse rod (A) and cone (B) outer segments. The principle of the 
phototransduction is similar in both cell types. In the dark, the cyclic nucleotide-gated (CNG) channel 
(CNGA1/B1 in rods and CNGA3/B3 in cones) of the outer membrane is kept open by high 
concentrations of cyclic guanosine monophosphate (cGMP) produced by retinal guanylyl cyclases 
(GCs) 1 and 2 (GC1/2 in rods, GC1 only in cones) present in the disc membrane. The resulting influx 
of Na+ and Ca2+ depolarizes the plasma membrane. Light activates rhodopsin (Rh) which in turn 
activates transducin (Gt1 in rods, Gt2 in cones) whose alpha subunit activates a phosphodiesterase 
(PDE6A/B in rods, PDE6C in cones) leading to hydrolysis of cGMP. The drop in the cGMP 
concentration leads to the closure of the CNG channel yielding to membrane hyperpolarization. Ca2+ 
is an important regulator of phototransduction. At high concentrations Ca2+ binds to guanylyl cyclase-
activating proteins (GCAPs; GCAP1/2 in rods, GCAP1 only in cones) leading to an inhibition of 
guanylyl cyclases. High levels of Ca2+ also lead to a slight reduction of the cGMP affinity of the CNG 
channel via CaM-mediated feedback inhibition. Ca2+ is cleared from the outer segment via a Na+-Ca2+-
K+-exchanger (NCKX1 in rods, NCKX2/4 in cones). At low Ca2+ levels GCAPs switch to the Ca2+-free 
form that is an activator of GCs. 
4. In Vivo Analysis of CNG Channel Function: Analysis of Genetic Mouse Models and  
Human Channelopathies 
Genetic studies have dramatically increased our knowledge on the significance of retinal CNG 
channels. The major findings of these studies will be summarized in the following sections.  
4.1. CNGA1 and CNGB1 
Mutations in the rod-specific CNGA1 or CNGB1 genes cause autosomal recessive retinitis 
pigmentosa (RP) [39,40] (Table 1). RP comprises a genetically diverse group of progressive 
degenerative retinal diseases affecting the photoreceptors of the retina [41,42]. The most common 
symptoms of RP include night blindness, progressive concentric reduction of the visual field, and 
Figure 2. (A,B) Phototransduction in mouse rod (A) and cone (B) outer segments. The principle of
the phototransduction is similar in both cell types. In the dark, the cyclic nucleotide-gated (CNG)
channel (CNGA1/B1 in rods and CNGA3/B3 in cones) of the outer membrane is kept open by high
concentrations of cyclic guanosine monophosphate (cGMP) produced by retinal guanylyl cyclases (GCs)
1 and 2 (GC1/2 in rods, GC1 only in cones) present in the disc membrane. The resulting influx of Na+
and Ca2+ depolarizes the plasma membrane. Light activates rhodopsin (Rh) which in turn activates
transducin (Gt1 in rods, Gt2 in cones) whose alpha subunit activates a phosphodiesterase (PDE6A/B in
rods, PDE6C in cones) leading to hydrolysis of cGMP. The drop in the cGMP concentration leads to the
closure of the CNG channel yielding to membrane hyperpolarization. Ca2+ is an important regulator of
phototransduction. At high concentrations Ca2+ binds to guanylyl cyclase-activating proteins (GCAPs;
GCAP1/2 in rods, GCAP1 only in cones) leading to an inhibition of guanylyl cyclases. High levels
of Ca2+ also lead to a slight reduction of the cGMP affinity of the CNG channel via CaM-mediated
feedback inhibition. Ca2+ is cleared from the outer segment via a Na+-Ca2+-K+-exchanger (NCKX1 in
rods, NCKX2/4 in cones). At low Ca2+ levels GCAPs switch to the Ca2+-free form that is an activator
of GCs.
4. In Vivo Analysis of CNG Channel Function: Analysis of Genetic Mouse Models and
Human Channelopathies
Genetic studies have dramatically increased our knowledge on the significance of retinal CNG
channels. The major findings of these studies will be summarized in the following sections.
4.1. CNGA1 and CNGB1
Mutations in the rod-specific CNGA1 or CNGB1 genes cause autosomal reces ive retinitis
pigmentosa (RP) [39,40] (Table 1). RP comprises a gen tic lly diverse group of progressive degenerative
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retinal diseases affecting the photoreceptors of the retina [41,42]. The most common symptoms
of RP include night blindness, progressive concentric reduction of the visual field, and abnormal
accumulation of pigmentation in the retina [43]. Fast progressing RP can lead to legal blindness in
advanced stages. So far, RP has been mapped to >60 genes (http://www.sph.uth.tmc.edu/Retnet,
22 February 2018) encoding proteins involved in the visual transduction pathway or required for the
maintenance of the rod architecture. Depending on the genetic background, mutations in CNGA1
account for 1–8% of cases of autosomal recessive RP (arRP) [40,41,44–46]. Most of the identified
CNGA1 mutations cause deletions of important functional domains or result in defective membrane
trafficking [2,40,47,48]. As a result, the affected patients lack rod-mediated light responses. Mutations
in CNGB1 account for approx. 4% of arRP cases [39,41,49,50]. Although the known CNGB1 mutations
cause only minor deletions or single amino acid substitutions, the phenotype is comparable to the
severe RP phenotype in CNGA1 patients. So far, only a few CNGB1 mutations have been functionally
characterized. These mutations lead to protein instability, impaired channel targeting or functionally
inactive CNG channels [39,49,51,52].
Mice lacking Cnga1 have not been described so far. However, transgenic mice overexpressing
Cnga1 antisense mRNA were generated [53]. Although no functional characterization of these mice
has been reported, histological analysis revealed some morphological features of RP (e.g., reduced
number of photoreceptors, apoptotic death of retinal cells). A naturally occurring Cnga1 mutation has
been recently identified in a Shetland sheepdog breed with progressive retinal atrophy [54]. However,
functional characterization of the retinal phenotype is still missing.
Genetic deletion of Cngb1 in mice results in a phenotype that recapitulates the principal pathology
of RP patients. In particular, Cngb1 knockout (KO) mice have strongly diminished rod photoreceptor
function and impaired rod-mediated vision [55–57]. The early functional defects are followed by
a progressive degeneration of rods and secondary degeneration of primarily non-affected cones.
The degeneration process is rather slow and results in loss of about 50% of rods at 6 months and 90%
at 12 months of age [55,57,58]. At the cellular level, the loss of Cngb1 induces down-regulation of
several proteins of the phototransduction cascade and degradation of the CNGA1 subunit. A naturally
occurring Cngb1 mutation was also identified in a Papillon dog breed with markedly reduced or
absent rod function, and accompanied by progressive retinal degeneration [59]. Comparative analysis
suggested that CNGB1-deficient RP patients and mouse and dog models have a similar phenotype
characterized by early loss of rod function and slow rod photoreceptor degeneration along with
a secondary decline in cone function [58].
4.2. CNGA3 and CNGB3
Mutations in either CNGA3 [60] or CNGB3 [61,62] cause achromatopsia (ACHM), also known as rod
monochromatism or total color blindness (Table 1). ACHM is an inherited eye disease associated with
congenital absence of cone photoreceptor function. In contrast to color blindness, in which changes in
expression of opsin genes merely affect spectral sensitivity but not the physiology of photoreceptors [63,64],
the complete unresponsiveness of cones in ACHM has grave consequences for vision, particularly with
respect to the densely cone-packed human fovea. Affected individuals suffer from strongly impaired
daylight vision, photophobia, nystagmus, and lack of color discrimination [65–67]. The prevalence of
ACHM is approximately 1:30,000 [68–70]. Currently, six genes have been linked to ACHM: ATF6,
CNGA3, CNGB3, GNAT2, PDE6C and PDE6H. Up to 80% of the patients carry mutations in the
genes CNGA3 and CNGB3 encoding the two subunits of the cone CNG channel. To date, more than
100 mutations in CNGA3 and more than 50 mutations in CNGB3 were found to cause inherited ACHM
in humans [71]. Mutations in CNGB3 (ACHM1) are more common in the general western population
and account for almost 50% of ACHM cases [72]. Most CNGB3 mutations are nonsense, frameshift
or splice mutations resulting in truncated or strongly impaired channel proteins [68,69]. A missense
mutation in the CNGB3 gene (S435F) was identified in colorblind individuals originating from the
Pingelap atoll of Micronesia [62]. In this small island ACHM is very frequent and affects nearly 10% of
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the native population [73]. Approximately 28% of patients in the western population carry mutations
in CNGA3 (ACHM2). In Middle East and Arabic populations, mutations in CNGA3 account for up to
60% of ACHM cases. The majority of CNGA3 mutations are missense mutations affecting only single
amino acid residues of the protein [68,69].
Loss of function mutations in CNGA3 result in non-functional cone CNG channels because
CNGB3 cannot form functional CNG channels in the absence of CNGA3 [2,47]. Genetic inactivation
of Cnga3 in mice leads to selective loss of cone-mediated light responses [74] accompanied by
progressive degeneration and cell death of cones [75]. An early hallmark of cone degeneration
is the strong accumulation of the second messenger cGMP, suggesting its involvement in the process of
degeneration [76,77]. Cone degeneration affects M- and S-cones differentially and cell death proceeds
significantly faster in ventral and nasal (S-cone-rich) than in dorsal and temporal (M-cone-rich) parts
of the retina. Ventral cones are almost completely missing after the third postnatal month whereas
residual dorsal cones are present even in aged knockout mice [75]. In addition, a naturally occurring
mouse model of achromatopsia—the cpfl5 mouse with a Cnga3 point mutation—was described with
a phenotype similar to the Cnga3 KO mouse [78]. Moreover, a sheep model of ACHM2 was identified
with diminished cone, but normal rod function [79,80]. Affected lambs were homozygous for a Cnga3
mutation which results in a premature stop codon [79]. Recently, two spontaneous canine models of
ACHM2 have been described [81]: a German shepherd, carrying a CNGA3/p.R424W mutation, and
a Labrador retriever with a CNGA3/p.V644del mutation.
Various animal models also exist for CNGB3-linked ACHM. Knockout of Cngb3 in mice strongly
impairs cone function and leads to progressive cone degeneration [82,83]. A residual cone function can
be observed in this model, most likely conferred by irregular homomeric CNGA3 channels. In addition
to the Cngb3 knockout (KO) mouse, multiple naturally occurring canine models exist that carry
recessive mutations in exon 6 or a genomic deletion of the entire Cngb3 gene [84]. The latter results in
a disease sharing the same clinical phenotype as human patients characterized by day blindness and
absence of cone function [85–88].
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Table 1. Overview of retinal CNG genes, associated human diseases, animal models, preclinical and clinical gene therapy studies. ID, www.clinicaltrials.gov identifier.
POC, proof-of-concept.
Gene
(Cell Type)
Associated Human
Disease Animal Models POC Studies
Preclinical
Safety Studies
Clinical Trials
(ID)
CNGA1
(rods)
Retinitis pigmentosa,
RP49
Cnga1 antisense expressing mice: retinal degeneration [53]
Canine model (missense mutation): Progressive retinal
atrophy [54]
- - -
CNGB1
(rods)
Retinitis pigmentosa,
RP45
Cngb1-deficient mice: impaired rod function and retinal
degeneration [55,56]
Canine model (missense mutation): impaired rod function
and retinal degeneration [89]
[58,90] - -
CNGA3
(cones) Achromatopsia, ACHM2
Cnga3-deficient mice: loss of cone function and cone
degeneration [74]
cpfl5 mouse: loss of cone function and cone cell
degeneration [91]
Sheep model (missense mutation): loss of cone function
and day blindness [80]
[76,78,92–96] [97–100] NCT02610582NCT02935517
CNGB3
(cones) Achromatopsia, ACHM1
Canine models (null-deletion or missense mutation): cone
degeneration [84]
Cngb3-deficient mice: Impaired cone function and cone
degeneration [82]
[101–103] [98,104–106] NCT02599922NCT03001310
Int. J. Mol. Sci. 2018, 19, 749 8 of 15
5. Gene Therapy for the Treatment of CNG Channelopathies
No curative treatment for CNG channelopathies (ACHM or RP) exists thus far and clinical
management is currently limited to specialized genetic counseling, the use of low vision aids, tinted
contact lenses or glasses to reduce symptoms of photophobia [70,107]. Our improved knowledge
on CNG channel biology and the availability of suitable animal models together with the advent of
recombinant adeno-associated virus (rAAV) vectors as efficient and safe retinal gene delivery tools has
led to the initiation of several promising gene therapy programs (Table 1).
ACHM and RP caused by mutations in CNG channels are both inherited in an autosomal recessive
manner. Therefore, most treatment approaches for CNG channelopathies focus on so-called gene
supplementation. Gene supplementation aims at complementing affected photoreceptor cells with
a healthy copy of the disease-causing gene. In the following paragraphs, we will provide an overview
on rAAV vectors, review current preclinical activities and finally summarize ongoing clinical trials.
rAAV vectors are based on AAVs, which are small (25 nm diameter), non-enveloped and non-
pathogenic parvoviruses with a genome packaging capacity of approx. 4.7 kb [108]. rAAV vectors
are devoid of most AAV genomic sequences and contain only short palindromic sequences, so called
inverted terminal repeats (ITRs), which flank the therapeutic gene expression cassette [108]. In recent
years, rAAV vectors have evolved as the gold standard gene delivery vector for retinal photoreceptors.
Their success is based on the fact that they are easy to produce at large scale and their small genome
can be easily manipulated [109,110]. Moreover, a large and growing number of naturally occurring
or engineered AAV capsids are available allowing for packaging of pseudotyped rAAV of different
serotypes with distinct properties, e.g., specificity for different cell types [111,112]. Finally, rAAVs are
generally considered as very safe gene therapy vectors with low immunogenicity and toxicity [113,114].
After transduction, in contrast to the native unmodified AAV that integrates into a preferred genome
site, the rAAV vector genome stays predominantly in an episomal state and no considerable integration
into the host genome has been reported [115–117].
6. Gene Therapy for CNG Channel-Linked RP
So far, no gene therapy approaches have been reported for CNGA1-linked RP (RP49). This is
most likely due to the lack of well-characterized animal models for this form of RP. For CNGB1-linked
RP (RP45) successful proof-of-concept studies for rAAV-based gene supplementation have been
reported in both the Cngb1 KO mouse model [90] and the Cngb1 mutant dog model [58]. To enable
efficient packaging and rod-specific expression of the relatively large full-length Cngb1 cDNA (~4 kb),
the two studies used an rAAV expression cassette with a short rod- [90] or photoreceptor-specific [58]
promoter combined with short regulatory elements (e.g., SV40 polyA). In both species, subretinal
injection of therapeutic rAAV gene supplementation vectors (serotype 5 or 8) led to (i) restoration
of CNG channel expression and localization, (ii) gain of retinal function and preservation of retinal
morphology and (iii) improvement of vision-guided behavior. Apart from the expression of full-length
CNGB1, rAAV treatment also restored normal levels of the otherwise degraded endogenous CNGA1
subunit of the rod CNG channel in this mouse model. Both proteins co-localized in rod outer segments
and formed regular CNG channel complexes within the treated area of the Cngb1 KO or mutant
retina, leading to significant morphological preservation and a delay of retinal degeneration. In the
electroretinographic analysis, substantial restoration of rod-driven light responses was observed.
Finally, treated Cngb1 KO mice as well as Cngb1 mutant dogs performed significantly better than
untreated controls in rod-dependent vision-guided behavior tests [58,90]. These promising results
facilitated the initiation of translational studies, which might culminate in a first in man clinical trial.
7. Gene Therapy for CNG Channel-Linked ACHM
Successful preclinical proof-of-concept animal studies for rAAV-based gene supplementation
therapy exist for CNGA3 and CNGB3 [76,78,92,93,101–103]. In these studies wildtype or tyrosine
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mutant AAV2, AAV5 or AAV8 vectors expressing the corresponding wildtype cDNAs under control of
cone-specific or ubiquitous promoters were used to evaluate rAAV-mediated gene supplementation as
a potential treatment of ACHM. The studies utilized engineered or naturally occurring mouse, dog
or sheep models of ACHM and reported beneficial effects of the treatment on cone-specific visual
function. Treated animals showed cone-driven light responses and showed structural preservation of
cone photoreceptors. Our group studied in detail the effect of rAAV-mediated gene supplementation
in Cnga3 KO mice [76,93]. In addition to the gain of retinal function, we could show that the treatment
also had beneficial effects on retinal morphology and degenerative cellular processes. For instance,
the therapy normalized pathologically elevated cellular cGMP levels in cones, delayed cone cell
death and diminished the inflammatory response of Müller glia cells that is a hallmark of retinal
degenerations [75]. Follow-up studies suggested that the therapeutic effect was long-lasting and could
be applied at more advanced disease stages (e.g., at three months of age) [93].
rAAV-based gene supplementation has proven equally effective in preclinical models of both
CNGA3- [76,78,92] and CNGB3-linked ACHM [101,103] with the only exception being the reduced
treatment efficiency of the treatment in advanced stage Cngb3 mutant dogs [101]. However, the efficiency
in this dog model could be improved when rAAV gene supplementation was combined with the
administration of ciliary neurotrophic factor (CNTF) which is known to cause a temporal deconstruction
of photoreceptor outer segments [102].
The very encouraging preclinical studies have led to the initiation of various translational projects
to bring gene supplementation therapies for CNGA3- and CNGB3-linked ACHM to the clinics (Table 1).
The first study to recruit patients was a phase I/II exploratory, dose-escalation study, which tests
safety and efficacy of a single dose subretinal injection of rAAV8.hCNGA3 in patients with ACHM
caused by CNGA3 mutations (clinicaltrials.gov identifier: NCT02610582) [118]. This clinical trial was
conducted by the RD-CURE consortium encompassing clinicians and researchers from the University
Eye Hospital Tübingen and the Ludwig-Maximilians-University Munich. Nine patients were treated
in this trial and publication of study results is expected in 2018. Three additional interventional phase
I/II clinical trials with ACHM patients are currently in progress. Two studies concern CNGB3-linked
ACHM (NCT02599922 and NCT03001310) and are sponsored by Applied Genetic Technologies Corp
(AGTC) and MeiraGTx UK II Ltd., respectively. These studies also have a non-randomized, open-label
and dose-escalation design and test safety and efficacy of rAAV2tYF-PR1.7-hCNGB3 (AGTC study)
or AAV2/8-hCARp.hCNGB3 (MeiraGTx study) in patients with ACHM caused by mutations in
CNGB3. Both studies started enrolling patients in 2016. Another phase I/II clinical trial testing
safety and efficacy of rAAV2tYF-PR1.7-hCNGA3 in patients with CNGA3-linked ACHM sponsored
by AGTC (NCT02935517) enrolled the first patient in May 2017. These studies together bring hope to
patients with CNG channel-linked eye diseases and suggest that gene therapy products targeting CNG
channelopathies could follow the path of Luxturna® (voretigene neparvovec-rzyl), the first in class
rAAV gene therapy product for the treatment of biallelic RPE65 mutation-linked retinal dystrophy,
which recently received marketing authorization from the U.S. Food and Drug Administration. Pricing
negotiations for Luxturna® are ongoing and we will have to wait and see how affordable such
treatments will be.
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